Introduction {#Sec1}
============

Essential thrombocythaemia (ET) is a chronic myeloproliferative neoplasm (MPN) characterized by the overproduction of platelets by megakaryocytes \[[@CR1]\]. The median age at diagnosis of ET is approximately 65--70 years with its incidence increasing with age \[[@CR2], [@CR3]\]. Previous retrospective studies suggest that patients with ET aged \>60 years have an increased risk of thrombotic events \[[@CR4], [@CR5]\]. However, previous randomized controlled trials suggest that thrombosis risk is reduced when patients are treated with cytoreductive therapy \[[@CR6], [@CR7]\]. Thus, according to international guidelines, high-risk patients with ET (patients \>60 years of age; history of thrombohaemorrhagic events; initial platelet count \>1500 × 10^9^/L) should be considered for cytoreductive therapy \[[@CR8]\].

Hydroxycarbamide (HC) is currently recommended for first-line therapy in high-risk patients with ET of all ages, although it should be used with caution in patients aged \<40 years \[[@CR8]\]. Anagrelide is approved for second-line treatment of ET in Europe \[[@CR9]\]. Both HC and anagrelide have been used in patients with a wide range of ages \[[@CR6], [@CR10]--[@CR17]\]. Since the overall population with ET are of advanced age, we believe it would be of value to more closely assess the very elderly patients (aged \>80 years), for whom different treatment decisions may be appropriate. Elderly patients are known to have greater thrombotic risk than younger patients in the general population \[[@CR18]\] and this risk is already increased in patients with ET. To date, there has been limited information reported regarding treatment practice in very elderly patients with ET \[[@CR19]\].

EXELS (Evaluation of Xagrid Efficacy and Long-term Safety) is a phase IV study, designed to monitor the safety of anagrelide and other cytoreductive therapies in patients with ET in routine clinical practice. Additional objectives include improving the understanding of the risks involved in long-term use of cytoreductive agents in ET. The aim of this analysis is to characterize the baseline features and management of patients with ET aged \>80 years, who were enrolled in the EXELS study.

Design and Methods {#Sec2}
==================

Trial Design {#Sec3}
------------

This is an ongoing phase IV non-interventional post-approval commitment study observing high-risk patients with ET who are treated with cytoreductive therapy. The EXELS study (ClinicalTrials.gov identifier NCT00567502; Protocol: SPD422-401) is being conducted in 13 European countries: Denmark, Finland, France, Germany, Greece, Ireland, Italy, The Netherlands, Norway, Portugal, Spain, Sweden and the United Kingdom. The first patient entered the study in May 2005 following local ethics committee approval at all participating centres. Predefined clinical events and biological data (including full blood counts) were collected from each patient at the time of registration and every 6 months thereafter for 5 years, using an electronic data capture system. The last patient was registered in April 2009 and the study will be completed in June 2014. This analysis was performed on a data-cut taken in March 2011. The EXELS study is non-interventional and no comparisons are made between groups due to the non-interventional nature of the study.

Participants {#Sec4}
------------

Patients with a diagnosis of ET according to the World Health Organization \[[@CR1]\] and/or Polycythemia Vera Study Group criteria \[[@CR20]\] with one or more high-risk features (patients \>60 years of age; history of thrombohaemorrhagic events; initial platelet count \>1000 × 10^9^/L), and receiving cytoreductive therapy, were eligible for study inclusion. Exclusion criteria were limited to the contraindications listed in the product information of the cytoreductive therapy. Written informed consent was obtained from all patients before entering the study.

Treatment {#Sec5}
---------

As this was a non-interventional study, the choice of cytoreductive therapy was determined prior to study registration and patients were managed according to local practice at the discretion of the investigators. Data related to predefined events (PDEs), suspected serious adverse reactions (SSARs), platelet count and any changes to medication were recorded at each 6-month update. Patients with multiple events of the same PDE category were only counted once for each treatment received. Thromboembolic events were defined in this analysis as the following PDEs: myocardial infarction (MI) and angina, stroke, transient ischaemic attack (TIA), intermittent claudication/digital ischaemia, and venous thromboembolic events. All safety evaluations and procedures were performed in accordance with routine clinical practice.

Statistical Methods {#Sec6}
-------------------

Ninety-five percent confidence intervals (CIs) for proportions were calculated and assessed for statistical significance using Chi-squared tests between reasons for treatment switch. A repeated measures analysis of variance (ANOVA) was used to determine whether the inclusion of treatment-naïve patients had affected the differences in platelet counts over time. The statistical software used was SAS version 9.2 (SAS Institute, Cary, NC, USA).

Results {#Sec7}
=======

Patients {#Sec8}
--------

A total of 3,598 patients were enrolled in the EXELS study, including 395 (11 %) very elderly (aged \>80 years) patients. Patient demographics and characteristics at study registration are shown in Table [1](#Tab1){ref-type="table"}. More than two-thirds (68.6 %) of the very elderly patients were female. As would be expected, a notable proportion of patients aged \>80 years had experienced a previous vascular or haemorrhagic event (42.2 %). Sixty-three of these patients (16 %) were treatment-naïve (defined as those who had only recently started cytoreductive treatment of any kind, within 6 months prior to registration).Table 1Summary of demographic and patient characteristics at study enrolment in patients aged \>80 years and the total EXELS populationCharacteristicAge categoryAge \>80 yearsTotalTotal,^a^ n (%)395 (11.0)3,598Female,^b^ n (%) \[95 % CI\]271 (68.6) \[66.7--70.5\]2,194 (61.0)Male,^b^ n (%) \[95 % CI\]124 (31.4) \[26.8--36.2\]1,389 (38.6)Haematological values, mean (SD) Hb (g/dL)11.96 (1.69)12.87 (1.635) Hct0.37 (0.05)0.39 (0.045) WBC (× 10^9^/L)7.44 (4.57)7.32 (4.075) Platelets (× 10^9^/L)485.71 (197.99)491.85 (227.84)Treatment-naïve,^a^ n (%) \[95 % CI\]63 (16.0) \[12.5--19.9\]694 (19.3)Anti-aggregatory therapy at registration,^a^ n (%) \[95 % CI\]274 (69.4) \[64.6--73.9\]2,505 (69.6)Haemorrhagic and vascular events prior to registration,^c^ n (%) \[95 % CI\]166 (42.2) \[37.3--47.3\]1,344 (37.4)Patients with missing data: ^a ^*n* = 2; ^b ^*n* = 15; ^c ^*n* = 29*CI* confidence interval, *Hb* haemoglobin, *Hct* haematocrit, *WBC* white blood cells

Treatment {#Sec9}
---------

The treatments patients aged \>80 years were receiving at enrolment are presented in Fig. [1](#Fig1){ref-type="fig"}. HC and anagrelide represent the two main cytoreductive treatments used as monotherapy in 91.4 % of the very elderly patients in EXELS. In the defined group, HC was most frequently prescribed (82.8 %) and anagrelide use was much less frequent (8.6 %). At enrolment into the EXELS study, 80.5 % (318/395) of the very elderly patients were receiving their first cytoreductive treatment but only 3.46 % (11/395) were receiving anagrelide. In total, 69.4 % of the very elderly patients were receiving anti-aggregatory therapy.Fig. 1Treatment at registration in patients aged \>80 years. '*Other*' includes interferon, busulphan, pipobroman, P32, and anagrelide and hydroxycarbamide in combination

Blood Cell Counts {#Sec10}
-----------------

### Platelet Count {#Sec11}

Platelet counts showed an initial reduction in all age groups from registration to 6 months, which was found to be significantly driven by the start of cytoreductive therapy in treatment-naïve patients (ANOVA; *p* \< 0.001). Following the initial reduction, platelet counts remained fairly consistent at a median count of \~430 × 10^9^/L in the very elderly patients (Fig. [2](#Fig2){ref-type="fig"}a).Fig. 2Evaluation of mean blood cell counts over time in patients aged \>80 years: (**a**) platelets, (**b**) haemoglobin, (**c**) haematocrit, (**d**) white blood cells

### Haemoglobin {#Sec12}

The median haemoglobin (Hb) values remained relatively stable in the range of 11.5--12.29 g/dL throughout the study in patients aged \>80 years (Fig. [2](#Fig2){ref-type="fig"}b).

### Haematocrit {#Sec13}

A slight variation over time (within 0.36--0.40) in median haematocrit counts was observed in patients aged \>80 years (Fig. [2](#Fig2){ref-type="fig"}c).

### White Blood Cells {#Sec14}

A slight variation in the median white blood cell count (between 5.6 and 7.1 × 10^9^/L) was observed in the very elderly patients over time (Fig. [2](#Fig2){ref-type="fig"}d).

It is important to note that the EXELS study is ongoing; therefore, for the entire clinical laboratory data reported at this data-cut, the *n*-numbers declined over time, as some patients had not completed the full 60-month observation period at the time of the data cut.

Treatment Switching {#Sec15}
-------------------

The frequency and reasons for first treatment switch, since study enrolment, are shown in Table [2](#Tab2){ref-type="table"}. Investigators determined the reason for switching therapy according to their best clinical judgement. Very elderly patients were more likely to be switched from anagrelide than from HC (47.1 vs. 17.4 %; 95 % CI for difference in proportion 12.4--46.9; Chi-squared test *p* \< 0.001). The Kaplan-Meier plots illustrate the time to first treatment switch based on survival analysis methodology (Fig. [3](#Fig3){ref-type="fig"}). In the total EXELS population, more patients had their therapy switched because of intolerance rather than loss of efficacy (28.1 vs. 12.3 %; 95 % CI for difference in proportion 12.2--19.3; Chi-squared test *p* \< 0.001). In patients aged \>80 years, the main reason for switch was intolerance/side effects. However, almost one-third of patients switched for 'other' reasons, which were largely due to lack of control of platelet counts and reductions in counts of white blood cells or Hb (data not shown). The reasons for first switch were similar between HC and anagrelide treatment in the overall study population. However, in very elderly patients, 0/16 reported treatment with anagrelide was non-efficacious compared with 8/57 (14 %) patients receiving HC, and 7/16 (43.8 %) anagrelide patients switched due to intolerance versus 18/57 (31.6 %) patients receiving HC.Table 2Treatment switching in patients aged \>80 years and the total EXELS populationVariableAge category^a^Age \>80 yearsTotal*Frequency of first switch*^*b*^Switch from any monotherapy91/395 (23.0) \[18.9--27.2\]902/3,596 (25.1)Switch from HC monotherapy57/327 (17.4) \[13.3--21.5\]455/2,340 (19.4)Switch from anagrelide monotherapy16/34 (47.1) \[30.3--63.8\]237/792 (30.0)*Reasons for first switch from HC*Intolerance/side effects18/57 (31.6) \[19.5--43.6\]127/455 (27.9)Non-efficacious8/57 (14.0) \[5.0--23.1\]55/455 (12.1)Subject preference1/57 (1.8) \[0--5.2\]9/455 (2.0)Other17/57 (29.8) \[17.9--41.7\]133/455 (29.2)Missing10/57 (17.5) \[7.7--27.4\]138/455 (30.3)Unknown5/57 (8.8) \[1.4--16.1\]10/455 (2.2)*Reasons for first switch from anagrelide*Intolerance/side effects7/16 (43.8) \[19.4--68.1\]69/237 (29.1)Non-efficacious0/16 (0.0) \[NA\]31/237 (13.1)Subject preference1/16 (6.3) \[0--18.1\]13/237 (5.5)Other (including economic)6/16 (37.5) \[13.8--61.2\]47/237 (19.8)Missing2/16 (12.5) \[0--28.7\]76/237 (32.1)Unknown0/16 (0.0) \[NA\]9/237 (3.8)*CI* confidence interval, *HC* hydroxycarbamide, *NA* not applicable^a^Values are expressed as n (%) \[95 % CI\]^b^Patients with missing data: *n* = 2Fig. 3Kaplan--Meier estimates for first treatment switch in patients aged \>80 years

Predefined Clinical Events {#Sec16}
--------------------------

The total numbers of predefined clinical events (PDEs), and details of notable PDEs, are presented in Table [3](#Tab3){ref-type="table"}. In the \>80 years group, 27.3 % of patients experienced at least one PDE. The most common PDEs reported in the very elderly age group were death (non-PDE related; 11.1 %), other cardiovascular (CV) symptoms (5.8 %), haematological transformation (3.8 %), congestive heart failure (CHF; 3.3 %), and MI and angina (2.8 %). There was no association observed between treatment received and occurrence of CHF or CV symptoms PDEs (data not shown).Table 3Numbers of patients with predefined events (PDEs) and numbers of PDEs by age categoryVariableAge categoryAge \>80 years (*n* = 395)Total (*n* = 3596)^a^n (%) \[95 % CI\]Eventsn (%)EventsAll PDEs reported108 (27.3) \[22.9--31.7\]167636 (17.7)911Notable individual PDEs MI and angina11 (2.8) \[1.2--4.4\]1359 (1.6)66 Stroke5 (1.3) \[0.2--2.4\]649 (1.4)55 TIA4 (1.0) \[0.0--2.0\]633 (0.9)38 Intermittent claudication/digital ischaemia2 (0.5) \[0.0--1.2\]212 (0.3)15 Venous thromboembolic events7 (1.8) \[0.5--3.1\]844 (1.2)49Thromboembolic events^b^ total25 (6.3) \[3.9--8.7\]35186 (5.2)223Congestive heart failure13 (3.3) \[1.5--5.1\]1435 (1.0)36Major haemorrhage10 (2.5) \[1.0--4.1\]1258 (1.6)69Other cardiovascular symptoms23 (5.8) \[3.5--8.1\]29129 (3.6)159Transformation^c^15 (3.8) \[1.9--5.7\]15106 (2.9)113Non-PDE death44 (11.1) \[8.0--14.2\]44103 (2.9)103*CI* confidence interval, *MI* myocardial infarction, *TIA* transient ischaemic attack^a^Patients with missing data: *n* = 2^b^Thromboembolic events defined as: MI and angina, stroke, TIA, intermittent claudication/digital ischaemia, venous thromboembolic events. *Note:* Some patients experienced more than one thromboembolic event^c^Transformation to: acute leukaemia, myelodysplasia, myelofibrosis and 'other'

The most common type of haematological transformation that occurred in the total EXELS population was myelofibrosis (*n* = 49, 1.4 %), followed by acute leukaemia (*n* = 37, 1.0 %) and 'other', including transformation to myelodysplasia (*n* = 27, 0.8 %). In patients aged \>80 years, acute leukaemia (*n* = 7, 1.8 %) and myelofibrosis (*n* = 4, 1.0 %) were also the most frequent transformations.

Thromboembolic events were experienced in 6.3 % (25/395) of patients \>80 years and 5.2 % (186/3,596) of the total EXELS cohort (Table [3](#Tab3){ref-type="table"}).

Discussion {#Sec17}
==========

Patients {#Sec18}
--------

This prospective observational study of 3,598 patients with ET includes, to our knowledge, the largest population of patients with ET studied to date, including 395 patients aged \>80 years. Sparse data are available on the treatment of very elderly patients with ET. Notably, Palandri et al. reported data on 118 patients with ET aged \>75 years, who they classified as very elderly \[[@CR19]\]. They retrospectively analysed 326 consecutive patients with ET diagnosed at \>60 years, although no patients aged \>75 years received anagrelide and, perhaps because of this, only 5.3 % discontinued HC because of adverse effects. The information collected from EXELS provides valuable insight into the treatment of these very elderly patients in clinical practice.

Treatment {#Sec19}
---------

The vast majority of very elderly patients were receiving HC and although anagrelide was the next most frequently used agent, the proportion of patients receiving it was low (8.6 %). These results suggest that the expert recommendations for ET therapy are applied by physicians across Europe \[[@CR8]\].

The proportion of patients who were receiving their first cytoreductive treatment, at the time of entering the EXELS study, increased with patient age. The high proportion of very elderly patients receiving first-line HC is probably due to the fact that there is broad agreement among physicians that HC is the treatment of choice for very elderly patients and because HC is well tolerated in general. Concerns regarding the potential leukaemogenicity of HC are less relevant for older patients than younger ones, since their life expectancy is reduced. Furthermore, physicians may be reluctant to use anagrelide in older patients due to the recognized inotropic effects \[[@CR9]\], making HC the agent of choice and options for switch limited. However, our results have shown that anagrelide can be effective and well tolerated, and provides a good alternative treatment option to busulphan, in very elderly patients for whom HC is unsuitable. Indeed, Italian guidelines recommend the continuation of anagrelide in patients aged \>60 years for as long as it continues to be effective \[[@CR26]\].

Blood Cell Counts {#Sec20}
-----------------

The initial reduction in platelet counts that was observed in all age groups was shown to be significantly affected by the treatment-naïve population. When these patients were removed from the analysis, the platelet counts remained fairly consistent.

The data suggest that the 'target platelet count', the point at which platelet counts are allowed to bottom-out, is \~450 × 10^9^/L for the very elderly patients in clinical practice. The criteria for a complete haematological response with ET therapy published by the European LeukemiaNet (ELN) include a target platelet count below 400 × 10^9^/L \[[@CR8]\]. It is a positive finding that these very elderly patients achieved levels that were close to target. Physicians may be particularly stringent about achieving low platelet counts in very elderly patients as this population has a higher incidence of previous vascular events (also shown in this study), which is a major risk factor for recurrent thrombosis. The ELN guidelines also include the following criteria in the definition of complete haematological response: normal spleen size on imaging, white blood cell count below 10 × 10^9^/L, and absence of disease-related symptoms \[[@CR8]\]. However, since EXELS predates the publication of these guidelines, these criteria were not considered in the study design and these data were not collected. Response rates were judged only on platelet levels.

Although anaemia has been reported with both of the major therapeutic agents used in the treatment of myeloproliferative neoplasms, the Hb values did not change over time in these patients. Anaemia is defined as a Hb value of \<12 g/dL in adult females and \<13 g/dL in adult males \[[@CR21]\]. The mean baseline Hb levels in the very elderly population were 12.0 g/dL, with the median values ranging from 11.5 to 12.3 g/dL over time. Since more than two-thirds of these patients were female, the Hb levels were on the low side of the normal range, which may be due to the large proportion of patients receiving treatment with HC \[[@CR22]--[@CR25]\].

Treatment Switching {#Sec21}
-------------------

The proportion of very elderly patients switching from anagrelide was 47.1 vs. 17.4 % from HC. The reason for first switch from HC or anagrelide was more often because of intolerance than loss of efficacy. Similar proportions of patients switched from HC because of lack of efficacy in our study and that of Palandri et al \[[@CR19]\]. Elderly patients have more frequent cardiac abnormalities than younger patients, which may make them more prone to switch treatment if they experience tachycardia or palpitations while receiving anagrelide. A further explanation for high levels of switching from anagrelide in older patients may be that various national guidelines suggest that HC, pipobroman or busulphan are preferable for the treatment of the oldest patients with ET \[[@CR8], [@CR26]\]. However, the small number of very elderly patients treated with anagrelide in EXELS (*n* = 34) precludes the formation of any strong conclusions concerning treatment switching. Low rates of switching therapy because of inefficacy (Table [2](#Tab2){ref-type="table"}), along with almost normal target platelet count observed in patients \>80 years, show that cytoreductive therapy in very elderly patients is effective. Indeed, tolerance is the main issue in managing patients of all ages with ET in clinical practice and is a particular concern in very elderly patients.

Predefined Clinical Events {#Sec22}
--------------------------

Overall, 108 patients aged \>80 years experienced a total of 167 PDEs, including vascular complications (*n* = 90), haematological transformation (to acute leukaemia or myelofibrosis; *n* = 15) and non-PDE deaths (*n* = 44). However, no new safety concerns were observed in these patients. Thromboembolic events happen in patients with ET, irrespective of the use of cytoreductive therapy, and elderly patients are also recognized to have a slightly increased risk \[[@CR18]\]. The very elderly patients in the study by Palandri et al. also experienced a greater thrombotic risk than those aged \<75 years. \[[@CR19]\] Although data on the incidence of angina in a non-MPN population are available \[[@CR27]\], uncertainties concerning diagnostic definitions and data collection principles make comparisons with the EXELS population unreliable.

The incidence of stroke and TIA in the very elderly patients in the EXELS study was 1.3 and 1.0 %, respectively. In comparison, across Europe between 2001 and 2009, stroke and TIA accounted for 0.45 % of annual hospital admissions in adults aged ≥80 years (0.29 and 0.15 % each, respectively) \[[@CR27]\]. Therefore, these events were substantially more frequent in the very elderly population in EXELS than the European elderly population. Diseases of the circulatory system (not including angina, MI, ischaemic or pulmonary heart disease, cardiac arrhythmias, cerebrovascular diseases, atherosclerosis or varicose veins), which included pulmonary embolism and deep vein thrombosis, occurred in less than 0.3 % of European adults aged ≥80 years annually between 2001 and 2009 \[[@CR27]\]. In comparison, venous thromboembolisms occurred in 1.2 % of all patients in EXELS and 1.8 % of those aged \>80 years. Therefore, the risk of thromboembolisms was substantially raised in patients in EXELS and particularly so in those aged \>80 years versus the overall European population.

Of note, similar proportions of patients aged \>80 years and patients in the overall EXELS population experienced thromboembolic events.

Conclusion {#Sec23}
==========

In conclusion, here we describe an analysis of very elderly patients from the largest ever observational study of patients with ET, providing new data on ET management of these patients in clinical practice. The haematological response and normalization of platelet counts achieved with cautious management of these patients is particularly promising. It is also of interest to note that intolerance to cytoreductive therapy is the main reason for treatment switch, not only in these very elderly patients but in patients of all ages.

To summarize, well-tolerated and effective cytoreductive therapy has been achieved in patients aged \>80 years by following individual treatment modalities that appear in agreement with the recent ELN guidelines. These findings will be confirmed once the study is completed in June 2014.
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